Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 18/20 | 0.78 |
| ▸ | MAOA | P21397 | 14/20 | 0.78 |
| ▸ | MAOB | P27338 | 11/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL237944 | 0.88 | KDM1A (1.00) | KDM1AMAOAMAOB | |
| SCHEMBL2755995 | 0.88 | KDM1A (1.00) | KDM1AMAOAMAOB | |
| SCHEMBL237943 | 0.88 | KDM1A (1.00) | KDM1AMAOAMAOB | |
| SCHEMBL1287444 | 0.80 | KDM1A (0.77) | KDM1AMAOAMAOB | |
| SCHEMBL240308 | 0.78 | KDM1A (1.00) | KDM1AMAOAMAOB | |
| SCHEMBL2755985 | 0.78 | KDM1A (1.00) | KDM1AMAOAMAOB | |
| SCHEMBL240309 | 0.78 | KDM1A (1.00) | KDM1AMAOAMAOB | |
| SCHEMBL6798638 | 0.75 | HTR1A (0.55) | KDM1AMAOAMAOB | |
| SCHEMBL6798636 | 0.75 | HTR1A (0.55) | KDM1AMAOAMAOB | |
| SCHEMBL238969 | 0.75 | KDM1A (0.77) | KDM1AMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2389362-A1 | PHENYLCYCLOPROPYLAMINE DERIVATIVES AND THEIR MEDICAL USE | Oryzon Genomics, S.A. (ES) | 2011-11-30 | — | — | EP | claimed |
| US-20110252680-A1 | Surface mounted frame arrangement | ROSE DISPLAYS, LTD | 2011-10-20 | — | — | US | claimed |
| WO-2010084160-A1 | PHENYLCYCLOPROPYLAMINE DERIVATIVES AND THEIR MEDICAL USE | ORYZON GENOMICS S.A. (ES) | 2010-07-29 | — | — | WO | claimed |
| EP-3716963-A1 | ENHANCING T-CELL FUNCTION AND TREATING A T-CELL DYSFUNCTIONAL DISORDER WITH A COMBINATION OF AN LSD INHIBITOR AND A PD1 BINDING ANTAGONIST | Epiaxis Therapeutics Pty Ltd (AU) | 2020-10-07 | — | — | EP | disclosed |
| EP-3185858-A1 | COMPOSITIONS FOR MODULATING CANCER STEM CELLS AND USES THEREFOR | University of Canberra (AU) | 2017-07-05 | — | — | EP | disclosed |
| EP-3013424-A1 | METHODS AND COMPOSITIONS FOR MODULATING CANCER STEM CELLS | University of Canberra (AU) | 2016-05-04 | — | — | EP | disclosed |
| WO-2016029262-A1 | COMPOSITIONS FOR MODULATING CANCER STEM CELLS AND USES THEREFOR | UNIVERSITY OF CANBERRA (AU) | 2016-03-03 | — | — | WO | disclosed |
| WO-2014205511-A1 | METHODS AND COMPOSITIONS FOR MODULATING CANCER STEM CELLS | UNIVERSITY OF CANBERRA (AU) | 2014-12-31 | — | — | WO | disclosed |
| WO-2012047852-A2 | COMPOSITIONS AND METHODS FOR MODULATING IMMUNODEFICIENCY VIRUS TRANSCRIPTION | THE J. DAVID GLADSTONE INSTITUTES (US) | 2012-04-12 | — | — | WO | disclosed |
| EP-2389362-A1 | PHENYLCYCLOPROPYLAMINE DERIVATIVES AND THEIR MEDICAL USE | Oryzon Genomics, S.A. (ES) | 2011-11-30 | — | — | EP | disclosed |
| US-20110252680-A1 | Surface mounted frame arrangement | ROSE DISPLAYS, LTD | 2011-10-20 | — | — | US | disclosed |
| WO-2010084160-A1 | PHENYLCYCLOPROPYLAMINE DERIVATIVES AND THEIR MEDICAL USE | ORYZON GENOMICS S.A. (ES) | 2010-07-29 | — | — | WO | disclosed |